Drug Delivery and Therapeutic Impact of extended-release Acetylsalicylic Acid

References

• Mozaffarian D , BenjaminEJ, GoASet al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association . Circulation131 ( 4 ), e29 – e322 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention . Heart disease and stroke prevention address the nation’s leading killers ( 2011 ). www.cdc.gov/chronicdisease/resources/publications/aag/pdf/2011/heart-disease-and-stroke-aag-2011.pdf .
   Google Scholar
• Giorda CB , AvogaroA, MagginiMet al. Recurrence of cardiovascular events in patients with Type 2 diabetes: epidemiology and risk factors . Diabetes Care31 ( 11 ), 2154 – 2159 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• van der Heijden AA , Van’t RietE, BotSDet al. Risk of a recurrent cardiovascular event in individuals with Type 2 diabetes or intermediate hyperglycemia: the Hoorn Study . Diabetes Care36 ( 11 ), 3498 – 3502 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Haffner SM , LehtoS, RonnemaaT, PyoralaK, LaaksoM . Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction . N. Engl. J. Med.339 ( 4 ), 229 – 234 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Cubbon RM , AbbasA, WheatcroftSBet al. Diabetes mellitus and mortality after acute coronary syndrome as a first or recurrent cardiovascular event . PLoS ONE3 ( 10 ), e3483 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association . Position statement Section 8: cardiovascular disease and risk management . Diabetes Care38 ( Suppl. ), S49 – S57 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Smith SC Jr , BenjaminEJ, BonowROet al. The World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation . Circulation124 ( 22 ), 2458 – 2473 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Gasparyan AY , WatsonT, LipGY . The role of aspirin in cardiovascular prevention: implications of aspirin resistance . J. Am. Coll. Cardiol.51 ( 19 ), 1829 – 1843 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Grove EL . Antiplatelet effect of aspirin in patients with coronary artery disease . Dan. Med. J.59 ( 9 ), B4506 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vane JR . Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs . Nat. New Biol.231 ( 25 ), 232 – 235 ( 1971 ).
   PubMedGoogle Scholar
• Tantry US , BlidenKP, GurbelPA . Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation . J. Am. Coll. Cardiol.46 ( 9 ), 1705 – 1709 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Freynhofer MK , BrunoV, WojtaJ, HuberK . The role of platelets in athero-thrombotic events . Curr. Pharm. Des.18 ( 33 ), 5197 – 5214 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , MahlaE, AntoninoMJ, TantryUS . Response variability and the role of platelet function testing . J. Invasive Cardiol.21 ( 4 ), 172 – 178 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Tantry US , MahlaE, GurbelPA . Aspirin resistance . Prog. Cardiovasc. Dis.52 ( 2 ), 141 – 152 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Patrignani P , TacconelliS, PiazueloEet al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action . J. Thromb. Haemost.12 ( 8 ), 1320 – 1330 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Patrono C , García RodríguezLA, LandolfiR, BaigentC . Low-dose aspirin for the prevention of atherothrombosis . N. Engl. J. Med.353 ( 22 ), 2373 – 2383 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Cox D , MareeAO, DooleyM, ConroyR, ByrneMF, FitzgeraldDJ . Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers . Stroke37 ( 8 ), 2153 – 2158 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Pedersen AK , FitzGeraldGA . Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase . N. Engl. J. Med.311 ( 19 ), 1206 – 1211 ( 1984 ).
   PubMed Web of Science ®Google Scholar
• Tang M , MukundanM, YangJet al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol . J. Pharmacol. Exp. Ther.319 ( 3 ), 1467 – 1476 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Patrono C , CiabattoniG, PatrignaniPet al. Clinical pharmacology of platelet cyclooxygenase inhibition . Circulation72 ( 6 ), 1177 – 1184 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• Behnke O , ForerA . From megakaryocytes to platelets: platelet morphogenesis takes place in the bloodstream . Eur. J. Haematol. Suppl.61, 3 – 23 ( 1998 ).
   PubMedGoogle Scholar
• Eikelboom JW , HirshJ, SpencerFA, BaglinTP, WeitzJI . Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines . Chest141 ( Suppl. 2 ), Se89 – Se119S ( 2012 ).
   Web of Science ®Google Scholar
• Burch JW , StanfordN, MajerusPW . Inhibition of platelet prostaglandin synthetase by oral aspirin . J. Clin. Invest.61 ( 2 ), 314 – 319 ( 1978 ).
   PubMed Web of Science ®Google Scholar
• Grove EL , HvasAM, MortensenSB, LarsenSB, KristensenSD . Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease . J. Thromb. Haemost.9 ( 1 ), 185 – 191 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Patrignani P , FilabozziP, PatronoC . Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects . J. Clin. Invest.69 ( 6 ), 1366 – 1372 ( 1982 ).
   PubMed Web of Science ®Google Scholar
• Grove EL , HvasAM, KristensenSD . Immature platelets in patients with acute coronary syndromes . Thromb. Haemost.101 ( 1 ), 151 – 156 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Vaduganathan M , AlviarCL, ArikanMEet al. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome . Am. Heart J.156 ( 5 ), 1002 – 1002 ( 2008 ).
   Web of Science ®Google Scholar
• Mijovic R , KovacevicN, ZarkovM, StosicZ, CabarkapaV, MiticG . Reticulated platelets and antiplatelet therapy response in diabetic patients . J. Thromb. Thrombolysis40 ( 2 ), 203 – 210 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Arazi HC , DoinyDG, TorciviaRSet al. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery . Interact. Cardiovasc. Thorac. Surg.10 ( 6 ), 863 – 867 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Baigent C , BlackwellL, CollinsRet al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials . Lancet373 ( 9678 ), 1849 – 1860 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients . BMJ324 ( 7329 ), 71 – 86 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Simpson SH , GambleJM, MereuL, ChambersT . Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis . J. Gen. Intern. Med.26 ( 11 ), 1336 – 1344 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Berger JS , SallumRH, KatonaBet al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature . Am. Heart J.164 ( 2 ), 153 – 162 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Becker RC , MeadeTW, BergerPBet al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) . Chest133 ( Suppl. 6 ), S776 – S814 ( 2008 ).
   Web of Science ®Google Scholar
• Gurbel P , TantryUS . Monitoring of antiplatelet therapy . In : Platelets . MichelsonAD ( Eds ), Elsevier, Waltham, MA, USA, 602 – 612 ( 2013 ).
   Google Scholar
• Gurbel PA , BlidenKP, DiChiaraJet al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study . Circulation115 ( 25 ), 3156 – 3164 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Tantry US , GesheffM, LiuF, BlidenKP, GurbelPA . Resistance to antiplatelet drugs: what progress has been made?Expert. Opin. Pharmacother.15 ( 17 ), 2553 – 2564 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hanley AJ , KarterAJ, WilliamsKet al. Prediction of Type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study . Circulation112 ( 24 ), 3713 – 3721 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Tasdemir E , ToptasT, DemirC, EsenR, AtmacaM . Aspirin resistance in patients with Type II diabetes mellitus . Ups. J. Med. Sci.119 ( 1 ), 25 – 31 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cetin M , KiziltuncE, CetinZGet al. Acetylsalicylic acid resistance in patients with Type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease . Pak. J. Med. Sci.30 ( 3 ), 539 – 544 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hovens MM , SnoepJD, EikenboomJC, van der BomJG, MertensBJ, HuismanMV . Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review . Am. Heart J.153 ( 2 ), 175 – 181 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Rocca B , PetrucciG . Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms . Thrombosis2012, 376721 ( 2012 ).
   PubMedGoogle Scholar
• Fuster V , ChesebroJH, FryeRL, ElvebackLR . Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy . Circulation63 ( 3 ), 546 – 551 ( 1981 ).
   PubMed Web of Science ®Google Scholar
• Winocour PD , LaiminsM, ColwellJA . Platelet survival in streptozotocin-induced diabetic rats . Thromb. Haemost.51 ( 3 ), 307 – 312 ( 1984 ).
   PubMed Web of Science ®Google Scholar
• Larsen SB , GroveEL, HvasAM, KristensenSD . Platelet turnover in stable coronary artery disease – influence of thrombopoietin and low-grade inflammation . PLoS ONE9 ( 1 ), e85566 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gum PA , Kottke-MarchantK, PoggioEDet al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease . Am. J. Cardiol.88 ( 3 ), 230 – 235 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Salama MM , MoradAR, SalehMA, SabriNA, ZakiMM, ElSafadyLA . Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors . J. Clin. Pharm. Ther.37 ( 6 ), 630 – 636 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bednar F , OsmancikP, HlavickaJ, JedlickovaV, PaluchZ, VanekT . Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery . J. Thromb. Thrombolysis27 ( 4 ), 394 – 399 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kammerer I , BachJ, SaggauW, IsgroF . Functional evaluation of platelet aspirin resistance after on-pump coronary bypass grafting using multiple aggregation tests . Thorac. Cardiovasc. Surg.59 ( 7 ), 425 – 429 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Labuz-Roszak B , PierzchalaK, TyrpienK . Resistance to acetylsalicylic acid in patients with Type 2 diabetes mellitus is associated with lipid disorders and history of current smoking . J. Endocrinol. Invest.37 ( 4 ), 331 – 338 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Smith JP , HaddadEV, TaylorMBet al. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome . Hypertension59 ( 3 ), 719 – 725 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Fateh-Moghadam S , PlockingerU, CabezaNet al. Prevalence of aspirin resistance in patients with Type 2 diabetes . Acta Diabetol.42 ( 2 ), 99 – 103 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Zimmermann N , WenkA, KimUet al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery . Circulation108 ( 5 ), 542 – 547 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Zaccardi F , RoccaB, PitoccoD, TaneseL, RizziA, GhirlandaG . Platelet mean volume, distribution width, and count in Type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis . Diabetes Metab. Res. Rev.31 ( 4 ), 402 – 410 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lee EY , KimSJ, SongYJ, ChoiSJ, SongJ . Immature platelet fraction in diabetes mellitus and metabolic syndrome . Thromb. Res.132 ( 6 ), 692 – 695 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ibrahim H , SchuttRC, HannawiB, DeLaoT, BarkerCM, KleimanNS . Association of immature platelets with adverse cardiovascular outcomes . J. Am. Coll. Cardiol.64 ( 20 ), 2122 – 2129 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cesari F , MarcucciR, GoriAMet al. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study . Thromb. Haemost.109 ( 5 ), 846 – 853 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Slavka G , PerkmannT, HaslacherHet al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease . Arterioscler. Thromb. Vasc. Biol.31 ( 5 ), 1215 – 1218 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Henry P , VermilletA, BovalBet al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease . Thromb. Haemost.105 ( 2 ), 336 – 344 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Würtz M , HvasAM, JensenLOet al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis . Int. J. Cardiol.175 ( 2 ), 274 – 279 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• DiChiara J , BlidenKP, TantryUSet al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study . Diabetes56 ( 12 ), 3014 – 3019 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Capodanno D , PatelA, DharmashankarKet al. Pharmacodynamic effects of different aspirin dosing regimens in Type 2 diabetes mellitus patients with coronary artery disease . Circ. Cardiovasc. Interv.4 ( 2 ), 180 – 187 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Dusse LM , FreitasLG . Clinical applicability of reticulated platelets . Clin. Chim. Acta439, 143 – 147 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ingram M , CoopersmithA . Reticulated platelets following acute blood loss . Br. J. Haematol.17 ( 3 ), 225 – 229 ( 1969 ).
   PubMed Web of Science ®Google Scholar
• Kieffer N , GuichardJ, FarcetJP, VainchenkerW, Breton-GoriusJ . Biosynthesis of major platelet proteins in human blood platelets . Eur. J. Biochem.164 ( 1 ), 189 – 195 ( 1987 ).
   PubMedGoogle Scholar
• Guthikonda S , LevEI, PatelRet al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin . J. Thromb. Haemost.5 ( 3 ), 490 – 496 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Mangalpally KKR , Siqueiros-GarciaA, VaduganathanM, DongJF, KleimanNS, GuthikondaS . Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro . J. Thromb. Thrombolysis30 ( 3 ), 251 – 262 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Würtz M , GroveEL, WulffLNet al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets . JACC. Cardiovasc. Interv.3 ( 8 ), 828 – 835 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Perneby C , WallenNH, RooneyC, FitzgeraldD, HjemdahlP . Dose- and time-dependent antiplatelet effects of aspirin . Thromb. Haemost.95 ( 4 ), 652 – 658 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Ridker PM , MansonJE, BuringJE, MullerJE, HennekensCH . Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians . Circulation82 ( 3 ), 897 – 902 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Muller JE , ToflerGH, StonePH . Circadian variation and triggers of onset of acute cardiovascular disease . Circulation79 ( 4 ), 733 – 743 ( 1989 ).
   PubMed Web of Science ®Google Scholar
• Naderi SH , BestwickJP, WaldDS . Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients . Am. J. Med.125 ( 9 ), 882 – 887 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Laliberté F , BookhartBK, NelsonWWet al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism . Patient6 ( 3 ), 213 – 224 ( 2013 ).
   PubMedGoogle Scholar
• Patrick J , DillahaL, ArmasD, SessaW . A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation . Postgrad. Med.127 ( 6 ), 573 – 580 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• McQuaid KR , LaineL . Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials . Am. J. Med.119 ( 8 ), 624 – 638 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Brown N , MayJA, WilcoxRGet al. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis . Br. J. Clin. Pharmacol.48 ( 1 ), 57 – 62 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Donnelly MT , StackWA, RichardsonPet al. Microencapsulated aspirin, Asacard, reduces endoscopic damage in healthy volunteers compared with conventional encapsulated aspirin [abstract G0440] . Gastroenterology114, A107 ( 1998 ).
   Web of Science ®Google Scholar
• De Feo P , BorisJM, MaffeisC . Lifestyle modification strategies to counteract the world epidemic growth of obesity and diabetes . Biomed. Res. Int.2014, 640409 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Widmer RJ , LermanA . Endothelial dysfunction and cardiovascular disease . Glob. Cardiol. Sci. Pract.2014 ( 3 ), 291 – 308 ( 2014 ).
   PubMedGoogle Scholar